Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting
STARt-001 is the first clinical study to evaluate Marengo's novel, selective Vβ TCR agonist technology to promote in vivo expansion…
